When InO says no: understanding escape

被引：0
|
作者：
Boer, Judith M. [1 ]
Zwaan, C. Michel [1 ,2 ]
机构：
[1] Princess Maxima Ctr Pediat Oncol, Nijmegen, Netherlands
[2] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands
来源：
BLOOD | 2024年 / 144卷 / 01期
关键词：
ALC; absolute lymphocyte count; ANC; absolute neutrophil count; ENT; ear; nose; and throat; HPV; human papillomavirus; URTI; upper respiratory tract infection; INOTUZUMAB OZOGAMICIN; EXPRESSION;
D O I：
10.1182/blood.2024024713
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CD22 is expressed in almost all cases of B-cell acute lymphoblastic leukemia (B-ALL) and is therefore an attractive therapeutic target. In this issue of Blood , Zhao and colleagues identified genetic aberrations that impaired clinical response to the CD22-directed antibody-drug conjugate inotuzumab ozogamicin (InO) in adult patients with relapsed or refractory B-ALL. 1 Using extensive analysis of pre- and posttreatment patient samples, the authors identified genetic aberrations associated with primary and acquired resistance to InO.
引用
收藏
页码：2 / 4
页数：3
相关论文
共 50 条
12345